Bad Times in the Bay Area | GenomeWeb

The drug discovery and development company Exelixis will be laying off 270 people, or 40 percent of its workforce, reports the San Francisco Business Times. The company's drug discovery group will bear the brunt of the cuts. The company says that having lower compensation, lab supplies and clinical trial costs will save it $90 million through 2011.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.